{
  "type": "article",
  "title": "Moderna Stock Surges 177 Percent Following Cancer Vaccine Trial Success as Single-Day Investment Nearly Triples",
  "summary": "Shares of US biotech firm Moderna skyrocketed over 177 percent in a single trading session following successful late-stage trial results for its joint mRNA skin cancer vaccine with Merck.",
  "content": "Global equity markets witnessed extraordinary momentum in the pharmaceutical space as shares of American biotechnology firm Moderna experienced a historic rally during Thursday's trading session. Widely recognized for developing one of the primary COVID-19 vaccines during the global pandemic, the company saw an aggressive buying surge following breakthrough news regarding its pipeline cancer treatment. The announcement of successful late-stage clinical trial outcomes for a joint cancer vaccine triggered an immediate rush among investors, driving the stock up by more than 177 percent in a single day.\n\nBreakthrough Trial Results Spark Historic Single-Day Rally\nTrading in Moderna on the US stock exchanges started with intense bullish sentiment. The stock had closed at $62.51 in the preceding trading session. As trading opened on Thursday, aggressive purchasing pushed the share price past the $116 threshold within a brief period. The momentum continued unabated throughout the session, driving the stock up by over 177 percent to a new all-time high of $176.66. By the close of the market, Moderna shares settled at $174.38, reflecting an impressive single-day gain of 173 percent. Translated into Indian currency, the stock reached approximately ₹16,740 per share. Based on these movements, an investment of ₹1 lakh made on Thursday grew to approximately ₹2.76 lakh (or ₹2,77,000) by the end of the day.\n\nStrategic Collaboration with Merck Achieves Melanoma Milestones\nThe catalyst behind this remarkable market performance stems from Moderna's partnership with pharmaceutical giant Merck. Both organizations confirmed that their investigational mRNA cancer treatment vaccine successfully achieved its primary targets in late-stage clinical testing for melanoma. Melanoma represents a highly aggressive form of skin cancer, making this trial milestone a major clinical breakthrough. The positive trial data reassurances resonated strongly across global capital markets, creating high demand for Moderna shares and solidifying its status as a high-performing multibagger stock.\n\nConsistent Multibagger Returns Across Extended Timeframes\nBeyond its single-day surge, Moderna's stock performance has demonstrated extraordinary growth over longer investment horizons. Over the past year, the company's shares have multiplied investor capital sixfold, delivering a massive 548.49 percent return over the 12-month period. Mathematically, a capital allocation of ₹1 lakh in Moderna shares one year ago would have expanded to roughly ₹6 lakh today. Additionally, the stock has appreciated by 250 percent over the past six months and recorded a gain of nearly 194 percent over the past month alone, highlighting sustained investor confidence in its commercial and therapeutic roadmap.\n\nWhat this means for you\nFor Global Investors: The massive single-day rally underscores how clinical trial milestones in biotech firms can generate rapid capital appreciation.\n\nFor Healthcare Context: Positive late-stage trial results for mRNA melanoma treatment signal potential progress in next-generation cancer therapeutics.\n\nQuestions & Answers\n\n1. How much did Moderna stock surge in a single day?\nModerna shares jumped over 177 percent during intra-day trading, reaching a record high of $176.66.\n\n2. At what price did Moderna shares close after the rally?\nThe stock closed at $174.38, representing a 173 percent gain from its previous close of $62.51.\n\n3. What caused the massive rally in Moderna stock?\nThe surge was driven by news that Moderna and Merck successfully achieved key milestones in late-stage clinical trials for their mRNA skin cancer vaccine.\n\n4. What has been Moderna's 1-year stock return?\nModerna shares have delivered a 548.49 percent return over the past year, multiplying investor capital nearly six times.",
  "url": "https://trendkia.com/en/market/kainsara-vaiksina-trayala-men-saphalata-se-moderna-ke-sheyara-177-pratishata-uchhale-niveshakon-ki-snpatti-eka-dina-men-hui-paune--18988",
  "category": "Market",
  "publishedAt": "2026-08-20",
  "tags": [
    "Moderna",
    "Merck",
    "Cancer Vaccine",
    "Stock Market",
    "Multibagger Stock",
    "Pharma Stocks",
    "US Markets"
  ],
  "language": "en",
  "site": "TrendKia"
}